Wade L. Thorstad
Papers
1
Total Citations
5
H-Index
1
About
Dr. Wade L. Thorstad is a leading radiation oncologist whose research has fundamentally reshaped treatment paradigms for head and neck cancers, particularly human papillomavirus-positive oropharyngeal squamous-cell carcinoma (HPV+ OPSCC). His most impactful work focuses on de-escalation therapy—strategically reducing the intensity of post-operative adjuvant treatment to minimize long-term toxicities without compromising survival outcomes. In his landmark non-randomized, multi-arm Phase 2 trial (2024, 5 citations), Dr. Thorstad demonstrated that risk-directed, de-escalated adjuvant therapy can achieve exceptional long-term efficacy in surgically resected locally advanced HPV+ OPSCC, offering patients a chance for cure with fewer debilitating side effects like swallowing dysfunction and xerostomia. This work directly addresses the critical need to balance oncologic control with quality of life, a challenge that has defined modern head and neck oncology. Dr. Thorstad’s contributions have influenced national treatment guidelines and inspired further prospective trials. His research continues to drive the field toward personalized, risk-adapted approaches, making him a pivotal figure in the evolution of de-escalation strategies for HPV-driven cancers.
Research Focus
Key Achievements
Top Papers
- 1